The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes using enfortumab vedotin for metastatic urothelial carcinoma stratified by prior response to immunotherapy: A single institution experience.
 
Christopher Eing Wee
Consulting or Advisory Role - Bayer HealthCare Pharmacuticals; Janssen
 
Amanda Nizam
Honoraria - Aptitude Health; Cleveland Clinic
Consulting or Advisory Role - AVEO
Travel, Accommodations, Expenses - ASCO
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer
 
Timothy D. Gilligan
No Relationships to Disclose
 
Yanwen Chen
No Relationships to Disclose
 
Kimberly Maroli
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - AVEO
 
Allison Martin
No Relationships to Disclose
 
Amanda Bonham
No Relationships to Disclose
 
David Lynn
No Relationships to Disclose
 
Neil Vyas
No Relationships to Disclose
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar; Nektar
Honoraria - Bristol Myers Squibb Foundation
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)